Eric S Daar

Summary

Affiliation: Los Angeles Biomedical Research Institute
Country: USA

Publications

  1. ncbi HIV-1 pol replication capacity predicts disease progression
    Eric S Daar
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center and the David Geffen School of Medicine at UCLA, Torrance, California 90502, USA
    AIDS 19:871-7. 2005
  2. ncbi Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance
    Eric S Daar
    Division of HIV Medicine, Department of Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California 90502, USA
    AIDS Res Hum Retroviruses 21:343-57. 2005
  3. ncbi Stromal cell-derived factor-1 genotype, coreceptor tropism, and HIV type 1 disease progression
    Eric S Daar
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, and the David Geffen School of Medicine at UCLA, Los Angeles, USA
    J Infect Dis 192:1597-605. 2005
  4. ncbi Human immunodeficiency virus and fertility care: embarking on a path of knowledge and access
    Eric S Daar
    Los Angeles Biomedical Research Institute, Harbor University of California, Los Angeles Medical Center, Torrance, California 90502, USA
    Fertil Steril 85:298-300; discussion 301. 2006
  5. ncbi Baseline HIV type 1 coreceptor tropism predicts disease progression
    Eric S Daar
    Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles UCLA Medical Center and the David Geffen School of Medicine at UCLA, Torrance, USA
    Clin Infect Dis 45:643-9. 2007
  6. ncbi Newer antiretroviral agents and how to use them
    Holly H Kim
    Division of HIV Medicine and Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center and the David Geffen School of Medicine at UCLA, 1124 West Carson Street, N 24, Torrance, CA 90502, USA
    Curr Infect Dis Rep 11:327-34. 2009
  7. ncbi Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1
    Eric S Daar
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson Street, N 24, Torrance, CA 90502, USA
    Ann Intern Med 154:445-56. 2011
  8. ncbi Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 204:1191-201. 2011
  9. ncbi Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men
    Lydia N Drumright
    Antiviral Research Center, Department of Medicine, University of California, San Diego, California, USA
    Sex Transm Dis 34:401-7. 2007
  10. ncbi Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease
    Thomas W Yoo
    Los Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles Medical Center, Divisions of HIV Medicine and Infectious Diseases, Department of Medicine, David Geffen School of Medicine, CA 90502, USA
    J Infect Dis 191:4-10. 2005

Detail Information

Publications57

  1. ncbi HIV-1 pol replication capacity predicts disease progression
    Eric S Daar
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center and the David Geffen School of Medicine at UCLA, Torrance, California 90502, USA
    AIDS 19:871-7. 2005
    ..To determine the influence of pol replication capacity on the natural history of HIV-1 infection...
  2. ncbi Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance
    Eric S Daar
    Division of HIV Medicine, Department of Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California 90502, USA
    AIDS Res Hum Retroviruses 21:343-57. 2005
    ..The recent developments of new antiretroviral drugs, including the use of boosted protease inhibitors, suggest that treatment strategies can limit the development of resistance...
  3. ncbi Stromal cell-derived factor-1 genotype, coreceptor tropism, and HIV type 1 disease progression
    Eric S Daar
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, and the David Geffen School of Medicine at UCLA, Los Angeles, USA
    J Infect Dis 192:1597-605. 2005
    ..Therefore, the increased frequency of X4-tropic viruses in subjects carrying the SDF1-3'A allele may explain the observed adverse effect that this allele has on the natural history of HIV-1 disease...
  4. ncbi Human immunodeficiency virus and fertility care: embarking on a path of knowledge and access
    Eric S Daar
    Los Angeles Biomedical Research Institute, Harbor University of California, Los Angeles Medical Center, Torrance, California 90502, USA
    Fertil Steril 85:298-300; discussion 301. 2006
    ....
  5. ncbi Baseline HIV type 1 coreceptor tropism predicts disease progression
    Eric S Daar
    Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles UCLA Medical Center and the David Geffen School of Medicine at UCLA, Torrance, USA
    Clin Infect Dis 45:643-9. 2007
    ..The impact of coreceptor tropism on the natural history of HIV-1 infection has not been fully explored...
  6. ncbi Newer antiretroviral agents and how to use them
    Holly H Kim
    Division of HIV Medicine and Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center and the David Geffen School of Medicine at UCLA, 1124 West Carson Street, N 24, Torrance, CA 90502, USA
    Curr Infect Dis Rep 11:327-34. 2009
    ....
  7. ncbi Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1
    Eric S Daar
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson Street, N 24, Torrance, CA 90502, USA
    Ann Intern Med 154:445-56. 2011
    ..Limited data compare once-daily options for initial therapy for HIV-1...
  8. ncbi Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 204:1191-201. 2011
    ..Due to higher virologic failure with ABC/3TC in the high HIV RNA stratum, blinded treatment was stopped in this group, but study follow-up continued for all patients...
  9. ncbi Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men
    Lydia N Drumright
    Antiviral Research Center, Department of Medicine, University of California, San Diego, California, USA
    Sex Transm Dis 34:401-7. 2007
    ..The objective of this study was to assess associations between unprotected anal intercourse (UAI) and substance use before and after HIV diagnosis among recently HIV-infected MSM...
  10. ncbi Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease
    Thomas W Yoo
    Los Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles Medical Center, Divisions of HIV Medicine and Infectious Diseases, Department of Medicine, David Geffen School of Medicine, CA 90502, USA
    J Infect Dis 191:4-10. 2005
    ..44; P=.037). The present study suggests that HCV infection and genotype may influence the natural history of HCV and HIV-1 disease...
  11. ncbi Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection
    Lydia N Drumright
    Department of Medicine, Antiviral Research Center, University of California, San Diego, CA 92093, USA
    J Acquir Immune Defic Syndr 43:344-50. 2006
    ..To examine within-subjects and combined between- and within-subjects associations between substance use and unprotected anal intercourse (UAI) among men who have sex with men (MSM) with recent HIV infection...
  12. ncbi Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity
    Jason D Barbour
    Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
    AIDS 20:2123-5. 2006
    ..Viral polRC was measured before starting ART in all subjects. We examined 243 individuals for a median 260 days after initiating ART. Low baseline polRC was associated with greater CD4 T-cell gains independent of virological responses...
  13. ncbi Platelet count is associated with plasma HIV type 1 RNA and disease progression
    Gunter Rieg
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Los Angeles, California 90095, USA
    AIDS Res Hum Retroviruses 23:1257-61. 2007
    ..001 for both). While there may be multiple explanations for these novel observations, they do generate hypotheses related to the potential influence platelets may have on the natural history of HIV-1 disease...
  14. ncbi Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men
    Pamina M Gorbach
    Department of Epidemiology, School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095 7353, USA
    J Acquir Immune Defic Syndr 47:639-43. 2008
    ..Examine associations among behaviors including substance use during sexual encounters, and transmitted HIV drug resistance in recently HIV-infected men who have sex with men (MSM)...
  15. ncbi The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals
    Christine M Hogan
    Department of Medicine, Medical College of Wisconsin, Milwaukee, USA
    J Infect Dis 205:87-96. 2012
    ..The benefits of antiretroviral therapy during early human immunodeficiency virus type 1 (HIV-1) infection remain unproved...
  16. ncbi Hepatitis C virus and death risk in hemodialysis patients
    Kamyar Kalantar-Zadeh
    Harold Simmons Center for Kidney Disease Research and Epidemiology, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, Torrance, CA 90509 2910, USA
    J Am Soc Nephrol 18:1584-93. 2007
    ..More diligent efforts to prevent and treat HCV infection may improve outcomes in MHD patients...
  17. ncbi Antiretroviral regimens for treatment-experienced patients with HIV-1 infection
    Meena Lagnese
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, David Geffen School of Medicine at UCLA, Division of HIV Medicine and Infectious Diseases, 1124 W Carson Street, N 24, Torrance, CA 90502, USA
    Expert Opin Pharmacother 9:687-700. 2008
    ..A significant number of treatment-experienced patients with HIV-1 infection develop drug-resistant virus...
  18. ncbi Potency and durability of antiretroviral therapy
    Eric S Daar
    Harbor-UCLA Research and Education Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Acquir Immune Defic Syndr 34:S111-7. 2003
  19. ncbi Behaviors of recently HIV-infected men who have sex with men in the year postdiagnosis: effects of drug use and partner types
    Pamina M Gorbach
    Department of Epidemiology, School of Public Health, University of California, Los Angeles, CA 90095 1772, USA
    J Acquir Immune Defic Syndr 56:176-82. 2011
    ..Assess behavior change of recently HIV-infected men who have sex with men (MSM)...
  20. ncbi Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccination
    Arumugam Balamurugan
    Division of Infectious Diseases, 37 121 CHS, UCLA Medical Center, 10833 LeConte Ave, Los Angeles, CA 90095, USA
    J Virol 82:2784-91. 2008
    ....
  21. ncbi Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains
    Otto O Yang
    37 121 Center for Health Sciences, Division of Infectious Diseases, 10833 LeConte Ave, UCLA Medical Center, Los Angeles, CA 90095, USA
    J Virol 79:860-8. 2005
    ..In conclusion, the rapid overgrowth of a superinfecting strain of HIV-1 of the same subtype raises major concerns for effective vaccine development...
  22. ncbi Hepatitis C infection in dialysis patients: a link to poor clinical outcome?
    Kamyar Kalantar-Zadeh
    Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson Street, C1 Annex, Torrance, CA 90509 2910, USA
    Int Urol Nephrol 39:247-59. 2007
    ..In this article, we review the link between the HCV infection and mortality in dialysis patients and compare HCV antibody to molecular methods to detect HCV infection in these individuals...
  23. ncbi Newer antiretroviral agents and how to use them
    Holly H Kim
    Division of HIV Medicine and Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center and the David Geffen School of Medicine at UCLA, 1124 W Carson Street, N 24, Torrance, CA 90502, USA
    Curr HIV/AIDS Rep 6:55-62. 2009
    ....
  24. ncbi Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia
    Otto O Yang
    Division of Infectious Diseases, Department of Medicine, Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    AIDS Res Hum Retroviruses 27:391-8. 2011
    ..Circumventing this natural history by pre-targeting CTL against more conserved epitopes with a vaccine could minimize the initial period of viral escape and immune damage during acute infection, improving long-term containment of HIV-1...
  25. ncbi Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection
    Amie L Meditz
    Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA
    J Infect Dis 203:442-51. 2011
    ..It is unknown whether sex and race influence clinical outcomes following primary human immunodeficiency virus type 1 (HIV-1) infection...
  26. ncbi Antiretroviral-drug resistance among patients recently infected with HIV
    Susan J Little
    Antiviral Research Center, Department of Medicine, University of California San Diego, San Diego 92103, USA
    N Engl J Med 347:385-94. 2002
    ..Among persons in North America who are newly infected with the human immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has been estimated at 1 to 11 percent...
  27. ncbi Antiretroviral resistance in clinical practice
    Eric S Daar
    Division of HIV Medicine, Harbor-UCLA Medical Center, David Geffen School of Medicine, University of California, Los Angeles, USA
    J Int Assoc Physicians AIDS Care (Chic Ill) 2:S4-18. 2003
  28. ncbi Improving adherence to antiretroviral therapy
    Eric S Daar
    University of California, Los Angeles, School of Medicine, USA
    AIDS Read 13:81-2, 85-6, 88-90. 2003
    ..Care providers need to be aware of the challenges and obstacles faced by their patients on antiretroviral regimens, and efforts to maximize adherence must begin even before the patient has the first prescriptions filled...
  29. ncbi Asymptomatic sexually transmitted infections in HIV-infected men who have sex with men: prevalence, incidence, predictors, and screening strategies
    Gunter Rieg
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center and David Geffen School of Medicine at UCLA, Los Angeles, California 90502, USA
    AIDS Patient Care STDS 22:947-54. 2008
    ..Our data support current Center for Disease Control and Prevention STI guidelines that recommend routine screening at increased frequency for HIV-infected MSM...
  30. ncbi Primary human immunodeficiency virus type 1 infection
    Malini Soogoor
    Division of HIV Medicine, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA 90502, USA
    Curr HIV/AIDS Rep 2:55-60. 2005
    ....
  31. ncbi Emerging resistance profiles of newly approved antiretroviral drugs
    Eric S Daar
    David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 16:110-6. 2008
    ..Daar, MD, at an International AIDS Society-USA Continuing Medical Education course in Los Angeles in March 2008. The original presentation is available as a Webcast at www.iasusa.org...
  32. ncbi Diagnostic discordance for hepatitis C virus infection in hemodialysis patients
    Kamyar Kalantar-Zadeh
    Division of Nephrology and Hypertension, Los Angeles Biomedical Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Am J Kidney Dis 46:290-300. 2005
    ....
  33. ncbi Barriers and unmet need for supportive services for HIV patients in care in Los Angeles County, California
    Amy Rock Wohl
    HIV Epidemiology Program, Los Angeles County Department of Public Health, Los Angeles, California 90005 4001, USA
    AIDS Patient Care STDS 25:525-32. 2011
    ..The reported reasons that services were not obtained suggest needed improvements in information dissemination on availability and location of HIV support services and more streamlined delivery of services...
  34. ncbi Treatment of primary HIV infection
    Eric S Daar
    Division of HIV Medicine, Harbor-UCLA Medical Center and Research and Education Institute, Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
    MedGenMed 4:15. 2002
  35. ncbi Transmission behaviors of recently HIV-infected men who have sex with men
    Pamina M Gorbach
    Department of Epidemiology, School of Public Health and Division of Infections Diseases, David Geffen School of Medicine, University of California, Los Angeles UCLA, Los Angeles, CA 90095 1772, USA
    J Acquir Immune Defic Syndr 42:80-5. 2006
    ..Analyze postdiagnosis behaviors of recently HIV-infected men who have sex with men (MSM)...
  36. ncbi New approaches and resolve may define the future of the global HIV pandemic
    Eric S Daar
    Division of HIV Medicine, Harbor-UCLA Medical Center, Los Angeles, California, USA
    Res Initiat Treat Action 12:8-10. 2007
  37. ncbi Antiretroviral rounds. The when, why and how of switching
    Keith Henry
    AIDS Clin Care 15:58-9. 2003
  38. ncbi Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection
    Andrew J Leigh Brown
    University of Edinburgh, Edinburgh, Scotland
    J Virol 78:2242-6. 2004
    ..This supports the view that variation in PR function is directly responsible for variation in fitness among strains in primary infection...
  39. ncbi Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance
    Lin Liu
    University of California San Diego, La Jolla, California 92093 0679, USA
    AIDS 22:835-9. 2008
    ..We compared eight genotypic interpretation methods to determine whether the method used would affect the rates of reported transmitted drug resistance...
  40. ncbi A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients
    Brookie M Best
    University of California, San Diego, San Diego, CA 92013, USA
    J Acquir Immune Defic Syndr 46:433-42. 2007
    ..To improve the utility of therapeutic drug monitoring (TDM) by defining the proportion of patients with and predictors of above or below target protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) concentrations...
  41. ncbi Incorporating novel virologic tests into clinical practice
    Eric S Daar
    Harbor University of California Los Angeles Medical Center, CA, USA
    Top HIV Med 15:126-9. 2007
    ..Daar, MD, at an International AIDS Society-USA Continuing Medical Education course in Chicago in May 2007. The original presentation is available as a Webcast at www.iasusa.org...
  42. ncbi Longitudinal analysis of CD8 T-cell responses to HIV and hepatitis C virus in a cohort of co-infected haemophiliacs
    Gillian C Harcourt
    Nuffield Department of Medicine, University of Oxford, UK
    AIDS 19:1135-43. 2005
    ..005). CONCLUSION: HCV infection has an impact on the phenotype of HIV-specific CD8 T cells. In this well-defined cohort, failure to maintain effective CD8 T-cell responses against HIV may contribute to disease progression...
  43. ncbi Measuring below the bar: what is it telling us?
    Eric S Daar
    AIDS 20:2385-7. 2006
  44. ncbi Molecular analysis of HIV strains from a cluster of worker infections in the adult film industry, Los Angeles 2004
    John T Brooks
    Epidemiology Branch, Division of HIV AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    AIDS 20:923-8. 2006
    ..As part of the investigation of this infection cluster, we evaluated whether viral strains collected from infected individuals were significantly related...
  45. ncbi Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population
    Andrew J Leigh Brown
    Department of Pathology, University of California, San Diego, California, USA
    J Infect Dis 187:683-6. 2003
    ..It revealed that resistant virus was transmitted only approximately 20% as frequently as expected from these patients. Individuals with primary resistance may become a significant source of resistant strains...
  46. ncbi Incidence of HIV superinfection following primary infection
    Davey M Smith
    JAMA 292:1177-8. 2004
  47. ncbi What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 1
    Peter J Ruane
    AIDS Read 14:421-6, 431-2, 434. 2004
    ..This article suggests treatment algorithms for those experiencing adverse events or the emergence of drug resistance with commonly used antiretroviral regimens...
  48. ncbi Antiretroviral rounds. Putting resistance to work
    Eric S Daar
    AIDS Clin Care 16:56, 60. 2004
  49. ncbi Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578)
    Glenn J Wagner
    RAND Corporation, 1776 Main Street, Santa Monica, CA 90407, USA
    AIDS 20:1295-302. 2006
    ..We conducted a randomized, multi-site, controlled trial of a cognitive-behavioral adherence intervention for patients initiating or changing an antiretroviral (ART) regimen...
  50. ncbi Isolation and characterization of an infectious HIV type 1 molecular clone from a patient with primary infection
    Hiroaki Takeuchi
    Department of Virology, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai 980-8575, Japan
    AIDS Res Hum Retroviruses 18:1127-33. 2002
    ..This HIV-1 DNA done will be a useful prototype for investigating the mechanism of HIV-1 transmission...
  51. ncbi Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes
    Manish Sagar
    Division of Human Biology, Fred Hutchinson Cancer Research Center, and Department of Medicine, University of Washington, Seattle, USA
    J Virol 78:7279-83. 2004
    ..S. women, one U.S. man, and one Kenyan man near the time of seroconversion. These findings suggest that early HIV-1 genetic diversity is not exclusive to women from Africa or to infection with any particular HIV-1 subtype...
  52. ncbi HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load
    Nicole Frahm
    Partners AIDS Research Center, Massachusetts General Hospital, No. 5214, 149 13th Street, Charlestown, MA 02129, USA
    J Virol 79:10218-25. 2005
    ..The data support an important role of the presented epitope in mediating relative control of HIV replication and help to better define immune correlates of controlled HIV infection...
  53. ncbi Characteristics of recently HIV-infected men who use the Internet to find male sex partners and sexual practices with those partners
    Davey M Smith
    University of California San Diego, 9500 Gilman Drive 0679, La Jolla, CA 92093, USA
    J Acquir Immune Defic Syndr 43:582-7. 2006
    ....
  54. ncbi What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 2
    Peter J Ruane
    AIDS Read 14:487-98. 2004
    ..This article builds on Part 1 by suggesting treatment algorithms for those experiencing adverse events or the emergence of drug resistance when using recommended or common alternative and emerging anti-HIV regimens...
  55. ncbi Lack of neutralizing antibody response to HIV-1 predisposes to superinfection
    Davey M Smith
    University of California San Diego, La Jolla, CA 92093 0679, USA
    Virology 355:1-5. 2006
    ..These data have considerable implications for vaccine development...
  56. ncbi Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1
    Matthew C Strain
    Department of Physics, University of California at San Diego, La Jolla, California, USA
    J Infect Dis 191:1410-8. 2005
    ..1 IUPM; P<.0005). These results suggest that treatment <6 months after seroconversion may facilitate long-term control of cellular reservoirs that maintain HIV-1 infection during treatment...
  57. ncbi Strategies for initiating combination antiretroviral therapy
    Michael L Tapper
    NYU School of Medicine and Lenox Hill Hospital, New York, New York, USA
    AIDS Patient Care STDS 19:224-38. 2005
    ..This paper reviews the results of recent clinical trials focusing on initial therapy and addresses important considerations when beginning antiretroviral therapy (ART) in treatment-naive individuals...